{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T20:30:55Z","timestamp":1786825855885,"version":"build-2736575974"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.0115","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T02:43:05Z","timestamp":1550889785000},"page":"e190115","source":"Crossref","is-referenced-by-count":55,"title":["Association of Missense Polymorphism in<i>HSD3B1<\/i>With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone"],"prefix":"10.1001","volume":"2","author":[{"given":"Masaki","family":"Shiota","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Akita University, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Uchiumi","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Akita University, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"issue":"5","key":"zoi190014r1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/iju.2016.23.issue-5","article-title":"Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.","volume":"23","author":"Shiota","year":"2016","journal-title":"Int J Urol"},{"issue":"6","key":"zoi190014r2","doi-asserted-by":"publisher","first-page":"R243","DOI":"10.1530\/ERC-12-0232","article-title":"Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer.","volume":"19","author":"Shiota","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"zoi190014r3","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"issue":"15","key":"zoi190014r4","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"zoi190014r5","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"zoi190014r6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1210\/er.2002-0050","article-title":"Molecular biology of the 3beta-hydroxysteroid dehydrogenase\/delta5-delta4 isomerase gene family.","volume":"26","author":"Simard","year":"2005","journal-title":"Endocr Rev"},{"issue":"5","key":"zoi190014r7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"issue":"4","key":"zoi190014r8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi190014r9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"7560","key":"zoi190014r10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"issue":"10","key":"zoi190014r11","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1470-2045(16)30227-3","article-title":"HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.","volume":"17","author":"Hearn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi190014r12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2017.0147","article-title":"Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer.","volume":"3","author":"Agarwal","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi190014r13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaoncol.2017.3164","article-title":"Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer.","volume":"4","author":"Hearn","year":"2018","journal-title":"JAMA Oncol"},{"issue":"14","key":"zoi190014r14","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.ejca.2015.06.122","article-title":"SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.","volume":"51","author":"Shiota","year":"2015","journal-title":"Eur J Cancer"},{"issue":"7","key":"zoi190014r15","doi-asserted-by":"publisher","first-page":"djw005","DOI":"10.1093\/jnci\/djw005","article-title":"Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7.","volume":"108","author":"Shiota","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi190014r16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/annonc\/mdw646","article-title":"Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.","volume":"28","author":"Shiota","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi190014r18","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi190014r19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"zoi190014r20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement.","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi190014r21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/pcan.2013.23","article-title":"Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.","volume":"16","author":"Fujimoto","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"zoi190014r22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/pros.v75.7","article-title":"Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.","volume":"75","author":"Wu","year":"2015","journal-title":"Prostate"},{"issue":"7604","key":"zoi190014r23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature17954","article-title":"Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.","volume":"533","author":"Li","year":"2016","journal-title":"Nature"},{"issue":"4","key":"zoi190014r24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamaoncol.2017.3159","article-title":"HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer.","volume":"4","author":"Almassi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi190014r25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clgc.2018.03.006","article-title":"Germline variant in HSD3B1 (1245 A &gt; C) and response to abiraterone acetate plus prednisone in men with new-onset metastatic castration-resistant prostate cancer.","volume":"16","author":"Hahn","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"zoi190014r26","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1172\/JCI98319","article-title":"HSD3B1(1245A&gt;C) variant regulates dueling abiraterone metabolite effects in prostate cancer.","volume":"128","author":"Alyamani","year":"2018","journal-title":"J Clin Invest"},{"issue":"6","key":"zoi190014r27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/bju.2006.97.issue-6","article-title":"Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men.","volume":"97","author":"Fukagai","year":"2006","journal-title":"BJU Int"},{"issue":"2","key":"zoi190014r28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/107327480901600210","article-title":"Impact of androgen deprivation therapy on racial\/ethnic disparities in the survival of older men treated for locoregional prostate cancer.","volume":"16","author":"Holmes","year":"2009","journal-title":"Cancer Control"},{"issue":"1","key":"zoi190014r29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bju.12937","article-title":"Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.","volume":"117","author":"Cooperberg","year":"2016","journal-title":"BJU Int"},{"key":"zoi190014r17","first-page":"170","volume-title":"TNM Classification of Malignant Tumors","author":"International Union Against Cancer","year":"1997","edition":"5th ed"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/2\/e190115\/17298561\/shiota_2019_oi_190014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T12:25:50Z","timestamp":1606566350000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.0115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0115","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]}}}